B · Normal
On September 22, Roche’s ENICEPATIDE met the two primary endpoints of its Phase II clinical trial.
Related telegraphs
[Four-connected Nanhua Bio: Cell therapy-related technologies and products are s
09-22 18:20
[Yahong Pharmaceutical: APL-2501 has completed the enrollment of the first subje
09-22 17:43
[AI pharmaceutical company Iambic backed by NVIDIA submits U.S. IPO application]
09-22 08:39
[Shenlian Bio: The Phase II clinical trial of UB-221 for the treatment of chroni
09-20 15:32
[State Food and Drug Administration: Establishing a market exclusivity period sy
09-20 10:54
[Lifang Pharmaceuticals: Celecoxib Tramadol Hydrochloride Tablets Clinical Trial
09-18 15:51
Comments